NasdaqCM:RCELBiotechs
Avita Medical (RCEL) Q1 Loss Of US$0.35 Per Share Tests Profitability Optimism
AVITA Medical (NasdaqCM:RCEL) opened Q1 2026 with revenue of US$19.3 million and a basic EPS loss of US$0.35, while trailing twelve month figures show revenue of US$72.3 million and a basic EPS loss of US$1.57. The company has seen quarterly revenue move from US$18.5 million in Q1 2025 to US$19.3 million in Q1 2026, alongside quarterly EPS losses shifting from US$0.53 to US$0.35. This keeps the focus firmly on how quickly margins can tighten and losses can be contained.
See our full analysis...